BR112022016132A2 - Composição farmacêutica, e, método de tratamento de doença infecciosa - Google Patents

Composição farmacêutica, e, método de tratamento de doença infecciosa

Info

Publication number
BR112022016132A2
BR112022016132A2 BR112022016132A BR112022016132A BR112022016132A2 BR 112022016132 A2 BR112022016132 A2 BR 112022016132A2 BR 112022016132 A BR112022016132 A BR 112022016132A BR 112022016132 A BR112022016132 A BR 112022016132A BR 112022016132 A2 BR112022016132 A2 BR 112022016132A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treatment
mannose
derivatives
infectious disease
Prior art date
Application number
BR112022016132A
Other languages
English (en)
Portuguese (pt)
Inventor
Manubhai Patel Nimesh
Original Assignee
Manubhai Patel Nimesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manubhai Patel Nimesh filed Critical Manubhai Patel Nimesh
Publication of BR112022016132A2 publication Critical patent/BR112022016132A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/2404—Serralysin (3.4.24.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022016132A 2020-03-02 2021-03-02 Composição farmacêutica, e, método de tratamento de doença infecciosa BR112022016132A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984135P 2020-03-02 2020-03-02
PCT/US2021/020411 WO2021178371A1 (en) 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Publications (1)

Publication Number Publication Date
BR112022016132A2 true BR112022016132A2 (pt) 2023-01-10

Family

ID=77463237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016132A BR112022016132A2 (pt) 2020-03-02 2021-03-02 Composição farmacêutica, e, método de tratamento de doença infecciosa

Country Status (9)

Country Link
US (1) US20210268075A1 (https=)
EP (1) EP4114407A4 (https=)
JP (1) JP7758906B2 (https=)
CN (1) CN115361953A (https=)
AU (1) AU2021229482A1 (https=)
BR (1) BR112022016132A2 (https=)
CA (1) CA3164767A1 (https=)
WO (1) WO2021178371A1 (https=)
ZA (1) ZA202209623B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007099639A (ja) * 2005-09-30 2007-04-19 Towa Chem Ind Co Ltd 除菌洗浄剤
WO2008035370A2 (en) * 2006-07-10 2008-03-27 Advanced Enzyme Technologies Limited Compositions for prevention and treatment of mastitis and metritis
EP2690105A1 (en) * 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
US20190000908A1 (en) * 2017-06-29 2019-01-03 Hms Laboratories Ltd. Compositions and methods for treating and/or preventing a urinary tract infection
US11707065B2 (en) * 2017-07-18 2023-07-25 Mc (Us) 3 Llc Method for biofilm dispersal
CN116115768B (zh) * 2022-12-01 2025-03-18 西南民族大学 一种抗菌剂及其制备方法和应用

Also Published As

Publication number Publication date
US20210268075A1 (en) 2021-09-02
ZA202209623B (en) 2023-12-20
EP4114407A1 (en) 2023-01-11
AU2021229482A1 (en) 2022-07-28
WO2021178371A1 (en) 2021-09-10
CN115361953A (zh) 2022-11-18
CA3164767A1 (en) 2021-09-10
JP2023515880A (ja) 2023-04-14
JP7758906B2 (ja) 2025-10-23
EP4114407A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BRPI0817396B8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
BR112022012269A2 (pt) Derivados de isoxazolina como pesticidas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
BR112017021002B8 (pt) composição antimicrobiana, uso de uma composição, método para reduzir substancialmente ou controlar a formação de colônias microbianas sobre ou em uma superfície, sanitizantes para as mãos, produto para o cuidado de ferimentos, produto para cuidado ou higiene pessoal, produto para animais domésticos, e, lenço antimicrobiano
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112016021700A2 (pt) Uso de aldeídos formulados com nanopartículas e/ou nanoemulsões para melhorar a resistência a doenças de plantas causadas por liberibacters
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
CL2019001194A1 (es) Extracto de una composición herbal como agente antimicrobiano y/o antibiopelícula.
BRPI0916885B8 (pt) composição farmacêutica
BR112023001283A2 (pt) Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
BR112021026076A2 (pt) Composto derivado introduzindo o grupo bifenila no novo ácido aminoalcanoico e composição farmacêutica antifúngica compreendendo o mesmo
BR112014030325A2 (pt) composição farmacêutica para tratar ou prevenir doença neurodegenerativa e alimento funcional
NI201900063A (es) Amidas aromáticas de ácido carboxílico
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112022002692A2 (pt) Agentes antimaláricos
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
BR112017028590A2 (pt) novo lipolantipeptídeo bicíclico, preparação e uso como agente antimicrobiano
BR112022016132A2 (pt) Composição farmacêutica, e, método de tratamento de doença infecciosa
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
BR112023018290A2 (pt) Inibidores da integrina alfa v beta 6 e alfa v beta 1 e usos dos mesmos